Literature DB >> 8013160

Etodolac clinical pharmacokinetics.

D R Brocks1, F Jamali.   

Abstract

Etodolac is a chiral nonsteroidal anti-inflammatory drug (NSAID) that is marked as the racemate. Currently, the drug is available in several countries for the treatment of arthritis and the alleviation of pain. Etodolac possesses several unique disposition features mainly due to its stereoselective pharmacokinetics. In plasma, the concentrations of the 'inactive' R-enantiomer are about 10-fold higher than those of the active S-enantiomer, an observation that is novel among the chiral NSAIDs. In common with other NSAIDs, the drug is highly plasma protein bound, and undergoes virtually complete biotransformation to oxidised metabolites and acyl-glucuronides. Etodolac is well absorbed, with maximal plasma concentrations attained within 1 to 2 hours in healthy volunteers. The area under the plasma concentration-time curve of racemic etodolac increases linearly with doses used clinically. The elimination half-life of etodolac is between 6 and 8 hours in plasma, and is similar for both enantiomers. The volume of distribution (Vd) of racemic etodolac is higher than that of most other NSAIDs mainly because of the extensive distribution of the S-enantiomer. The very large Vd of the S-enantiomer, compared with its antipode is, at least in part, due to its less extensive plasma protein binding. In addition to the unchanged drug, substantial concentrations of the acyl-glucuronides of etodolac are found in both plasma and the synovial fluid of patients with arthritis. A limited amount of conjugated etodolac is found in the bile of patients following cholecystectomy. Hepatic cirrhosis has no effect on the pharmacokinetics of racemic etodolac, although the effect of hepatic dysfunction on the pharmacokinetics of the individual enantiomers has yet to be determined. In elderly non-arthritic individuals with excellent kidney function, aging does not affect the pharmacokinetics of etodolac. The pharmacokinetics of the drug in patients with renal failure have not been published, and may be important because the acyl-glucuronides are renally cleared.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8013160     DOI: 10.2165/00003088-199426040-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  43 in total

1.  Covalent binding of etodolac acyl glucuronide to albumin in vitro.

Authors:  P C Smith; W Q Song; R J Rodriguez
Journal:  Drug Metab Dispos       Date:  1992 Nov-Dec       Impact factor: 3.922

2.  The dispositional enantioselectivity of indobufen in man.

Authors:  M Strolm Benedetti; E Frigerio; V Tamassia; G Noseda; J Caldwell
Journal:  Biochem Pharmacol       Date:  1992-05-08       Impact factor: 5.858

3.  The pharmacokinetics of etodolac in serum and synovial fluid of patients with arthritis.

Authors:  M Kraml; D R Hicks; M McKean; J Panagides; D Furst; J Furst
Journal:  Clin Pharmacol Ther       Date:  1988-05       Impact factor: 6.875

4.  Stereoselective gas chromatographic analysis of etodolac enantiomers in human plasma and urine.

Authors:  N N Singh; F Jamali; F M Pasutto; R T Coutts; A S Russell
Journal:  J Chromatogr       Date:  1986-10-31

5.  Bias in pharmacokinetics and clinical pharmacology.

Authors:  E J Ariëns; E W Wuis
Journal:  Clin Pharmacol Ther       Date:  1987-10       Impact factor: 6.875

6.  Pharmacokinetics of ketoprofen enantiomers in healthy subjects following single and multiple doses.

Authors:  R T Foster; F Jamali; A S Russell; S R Alballa
Journal:  J Pharm Sci       Date:  1988-01       Impact factor: 3.534

7.  The metabolic disposition of etodolac in rats, dogs, and man.

Authors:  M N Cayen; M Kraml; E S Ferdinandi; E Greselin; D Dvornik
Journal:  Drug Metab Rev       Date:  1981       Impact factor: 4.518

8.  Stereoselective disposition of ibuprofen enantiomers in man.

Authors:  E J Lee; K Williams; R Day; G Graham; D Champion
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

9.  Etodolac (1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid): a potent antiinflammatory drug. Conformation and absolute configuration of its active enantiomer.

Authors:  L G Humber; C A Demerson; P Swaminathan; P H Bird
Journal:  J Med Chem       Date:  1986-05       Impact factor: 7.446

10.  Etodolac, a novel antiinflammatory agent. The syntheses and biological evaluation of its metabolites.

Authors:  L G Humber; E Ferdinandi; C A Demerson; S Ahmed; U Shah; D Mobilio; J Sabatucci; B De Lange; F Labbadia; P Hughes
Journal:  J Med Chem       Date:  1988-09       Impact factor: 7.446

View more
  12 in total

1.  Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia.

Authors:  Markus Jensen; Andreas Engert; Florian Weissinger; Wolfgang Knauf; Eva Kimby; Christopher Poynton; Ira Anton Oliff; Mathias J Rummel; Anders Osterborg
Journal:  Invest New Drugs       Date:  2007-12-20       Impact factor: 3.850

2.  Development of an Enantioselective and Biomarker-Informed Translational Population Pharmacokinetic/Pharmacodynamic Model for Etodolac.

Authors:  Carolina de Miranda Silva; Adriana Rocha; Eduardo Tozatto; Lucienir Maria da Silva; Eduardo Antônio Donadi; Teresa Dalla Costa; Vera Lucia Lanchote; Stephan Schmidt; Jürgen B Bulitta
Journal:  AAPS J       Date:  2017-09-05       Impact factor: 4.009

3.  Chiral bioequivalence: effect of absorption rate on racemic etodolac.

Authors:  J R Boni; J M Korth-Bradley; L S Richards; S T Chiang; D R Hicks; L Z Benet
Journal:  Clin Pharmacokinet       Date:  2000-12       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of ibuprofen. The first 30 years.

Authors:  N M Davies
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

5.  Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis.

Authors:  T D Warner; F Giuliano; I Vojnovic; A Bukasa; J A Mitchell; J R Vane
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

Review 6.  Clinical pharmacokinetics of tiaprofenic acid and its enantiomers.

Authors:  N M Davies
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of naproxen.

Authors:  N M Davies; K E Anderson
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

8.  The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis.

Authors:  Siva Kumar Kolluri; Maripat Corr; Sharon Y James; Michele Bernasconi; Desheng Lu; Wen Liu; Howard B Cottam; Lorenzo M Leoni; Dennis A Carson; Xiao-kun Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-07       Impact factor: 11.205

9.  Etodolac in the management of pain: a clinical review of a multipurpose analgesic.

Authors:  N Bellamy
Journal:  Inflammopharmacology       Date:  1997       Impact factor: 4.473

10.  Single-dose safety and pharmacokinetic evaluation of fluorocoxib A: pilot study of novel cyclooxygenase-2-targeted optical imaging agent in a canine model.

Authors:  Maria Cekanova; Md Jashim Uddin; Alfred M Legendre; Gina Galyon; Joseph W Bartges; Amanda Callens; Tomas Martin-Jimenez; Lawrence J Marnett
Journal:  J Biomed Opt       Date:  2012-11       Impact factor: 3.170

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.